Father’s Day Offer: Get 35% OFF Health + Ancestry Service. Limit 3. Offer ends June 16.
Remember, you can always upgrade without having to spit again.
Ancestry
Service
Original Price: $119 Sale Price: $99
BuyAdd to cart
Health +
Ancestry
Service
Original Price: $229 Sale Price: $148
BuyAdd to cart
23andMe
+
PremiumTM
Original Price: $298 Sale Price: $148
First
Year
BuyAdd to cart
Membership renews at $69/peryr.
23andMe
+
Total HealthTM
$999
First
Year
BuyAdd to cart
Membership renews at $499/peryr.
Total Reports
Genotyping
ReportsGenotyping examines DNA variants at certain pre-identified positions in the genome. The specific variants we look at generally provide coverage of commonly known variations across the entire genome.
Genotyping
Reports Genotyping examines DNA variants at certain pre-identified positions in the genome. The specific variants we look at generally provide coverage of commonly known variations across the entire genome.
| 80+ | 150+ | 190+ | 190+ |
Exome Sequencing
ReportsΔLearn about Important Information for Total healthExome sequencing is an advanced genetic testing technique that focuses on decoding the exome of an individual's genome. The exome represents the protein-coding regions of genes, which make up only about 2% of the entire genome but contain the majority of genetic variants associated with disease risk.
Exome Sequencing
ReportsΔLearn about Important Information for Total health Exome sequencing is an advanced genetic testing technique that focuses on decoding the exome of an individual's genome. The exome represents the protein-coding regions of genes, which make up only about 2% of the entire genome but contain the majority of genetic variants associated with disease risk.
 | | |  Clinician-ordered advanced genetic testing and interpretations that screen for 55+ clinically actionable and under-diagnosed conditions. |
Ancestry FeaturesNow with 3000+ regions
50+
reports including:
See where your DNA is from out of 3000+ regions worldwide – and more. Population-specific reports with maps covering 3000+ regions, offering a granular view of your ancestry, plus immersive educational content. Reports included: Learn the origins of your maternal and paternal ancestors and where they lived thousands of years ago. Women can only trace their paternal haplogroup by connecting to a male relative - such as a father, brother, or paternal male cousin. This is because the paternal haplogroup is traced through the Y chromosome, which women do not inherit.
Americas (Caribbean, Mexico & Central America, Indigenous American, South America); East Asia (Chinese, Chinese Dai, Filipino & Austronesian, Indonesian, Thai, Khmer & Myanma, Japanese, Korean, Manchurian & Mongolian, Siberian, Vietnamese); Europe (Ashkenazi Jewish, British & Irish, Eastern European, Finnish, French & German, Greek & Balkan, Italian, Sardinian, Scandinavian, Spanish & Portuguese);Oceania (Melanesian); Central & South Asia (Bengali & Northeast Indian, Central Asian, Gujarati Patidar, Malayali Subgroup, Northern Indian & Pakistani, Southern Indian & Sri Lankan, Southern Indian Subgroup);Sub-Saharan Africa (African Hunter-Gatherer, Angolan & Congolese, Ethiopian & Eritrean, Ghanaian, Liberian & Sierra Leonean, Nigerian, Senegambian & Guinean, Somali, Southern East African, Sudanese); Western Asia & North Africa (Anatolian, Coptic Egyptian, Cypriot, Egyptian, Iranian, Caucasian & Mesopotamian, Levantine, North African, Peninsular Arab)
See how many Neanderthal variants you have, how that compares to others and what it means for you.
| | | |
Find and connect with relatives in the 23andMe database who share DNA with you.
| | | |
Start a family tree automatically based on your DNA.
| | | |
Get advanced filtering for DNA Relative Finder and access up to 5000 DNA relatives.
| | | |
Uncover your historical and ancient relatives, linking you to the past.
| | | |
Health Features
Including: BRCA1/BRCA2 (Selected Variants), Late-Onset Alzheimer's Disease, Type 2 Diabetes
( Reports and features that are "Powered by 23andMe Research" are developed by 23andMe scientists using data and insights gathered from thousands of customers who have consented to participate in our research.
| 10+ | 40+ | 40+ |
45+ reports including: Cystic Fibrosis, Sickle Cell Anemia, Hereditary Hearing Loss
| | | |
Including: Deep Sleep, Lactose Intolerance, Genetic Weight
| 5+ | 10+ | 10+ |
Opt in to easily input, track and download your family health history to share with your healthcare provider.
| | | |
Discover how your DNA may impact how your body processes certain medications with 6 new Pharmacogenetics reports.
| | | |
Our latest
Breast Cancer (females only), Prostate Cancer (males only) and Colorectal Cancer (certain ethnicities)
personalized
next steps.
| | | |
See how making healthy choices each day can greatly impact your health over time.
| | | |
Personalized and ongoing recommendations based on genetic and non-genetic data.
| | | |
Eligible participants may order in-person blood testing initiated by a clinician and get results in the 23andMe app.
| | Add-on | 2x/peryr |
Access to clinicians with training in genetics. Includes unlimited direct messaging, plus a dedicated virtual consultation annually.
| | | |
Trait Features
30+ traits including: Male Bald Spot, Sweet vs. Salty, Unibrow
| | | |
Other
Trace DNA through your close family and explore the genetic similarities and differences between you and family members.
| Ancestry only | | | Excluding exome |
Get access to new premium reports and features throughout the year.
| | | |
*The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. This report is for over-the-counter use by adults over the age of 18, and provides genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/
**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/
Δ triangleExome Sequencing and blood testing services are available to eligible customers upon completion of the intake questionnaire that must be reviewed, approved and ordered by a third-party clinician. Exome Sequencing is analyzed by a CLIA- and CAP-accredited laboratory. Blood testing is completed by Quest Diagnostics. All telehealth services are rovided in accordance with the Telehealth Terms and Consent Telehealth.
